All articles tagged with #epipen
A UK mom with a severe latex allergy must avoid balloons and rubber playground surfaces, limiting her ability to accompany her 7-year-old to parks and birthday parties. She has endured two life-threatening reactions that required emergency care, and now relies on her partner for outings while advocateing for speaking up about her allergy to prevent danger, even at the cost of embarrassment or social discomfort.
Timothy Howard died from a severe allergic reaction to a contaminated chocolate bar, highlighting the dangers of food allergies and the need for clearer food labeling and better emergency treatments. His family advocates for increased awareness and safety measures to prevent similar tragedies, emphasizing the importance of reading labels and timely treatment during allergic reactions.
NYU Langone doctor Kanokporn “Amy” Tangsuan, who had severe nut and dairy allergies, tragically died from anaphylaxis after dining at a Disney Springs restaurant despite informing the wait staff multiple times about her allergies. Her father revealed that she had always been vigilant about her allergies and carried an EpiPen. Tangsuan's widower has filed a wrongful death lawsuit against Disney and the restaurant. The family is seeking damages in excess of $50,000.
The New York City professional dancer, Órla Baxendale, who died from an allergic reaction to mislabeled cookies suffered such an intense anaphylactic shock that her EpiPen was ineffective, according to her family's lawyer. The attorney criticized Stew Leonard's supermarket for not listing peanuts in the cookie ingredients, calling the death "100% unquestionably preventable and avoidable." The family intends to seek justice through legal action, as they mourn the loss of the dancer, who was known for her carefulness and moved to New York City to pursue her passion for dance.
The U.S. Food and Drug Administration (FDA) has declined to approve Neffy, a needle-free nasal spray alternative to the EpiPen developed by ARS Pharma, citing the need for further study. Neffy, which would have been available by prescription, is intended to treat severe allergic reactions. The FDA stated that they require more evidence to support approval, and ARS Pharma will have the opportunity to conduct additional studies and reapply for approval. Following the news, ARS shares fell by approximately 58% in pre-market trading.
The FDA is set to approve the first ever needle-free alternative to the EpiPen, providing a new option for individuals with severe allergies. This alternative device, called Symjepi, delivers epinephrine through a spring-loaded mechanism instead of a needle, making it easier and less intimidating to use. The approval of this alternative could offer more accessibility and convenience for those in need of emergency treatment for severe allergic reactions.
An advisory committee of outside experts to the FDA voted in favor of ARS Pharmaceuticals’ EpiPen alternative for adults and children, which would be the first epinephrine nasal spray on the US market. The FDA advisory committee's vote was a surprise as multiple members questioned the nasal spray’s benefit-risk profile and called for some clinical data on the nasal spray to be produced before it can be approved. Meanwhile, the FDA has rejected ImmunityBio’s biologics license application for a specific bladder cancer, and the biotech’s shares tumbled about 50% before the opening bell Thursday.